Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Multiple sclerosis in the context of TNF blockade and inflammatory bowel disease.

× No keyword cloud information.

7 in total

1. Interaction of *HLA-DRB1***1501* and TNF-Alpha in a Population-based Case-control Study of Multiple Sclerosis.

Authors: Dhelia M Williamson; Ruth Ann Marrie; Allison Ashley-Koch; Glen A Satten
Journal: Immunol Infect Dis Date: 2013-09

Review 2. Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping.

Authors: Ippazio Cosimo Antonazzo; Emanuel Raschi; Luca Vignatelli; Elisa Baldin; Trond Riise; Roberto D'Alessandro; Fabrizio De Ponti; Elisabetta Poluzzi
Journal: Drug Saf Date: 2017-09 Impact factor: 5.606

3. Use of anti-TNF-α therapy in Crohn's disease is associated with increased incidence of multiple sclerosis.

Authors: Jagannadha Avasarala; Zain Guduru; Christopher J McLouth; Amanda Wilburn; Jeffrey Talbert; Paige Sutton; Brent S Sokola
Journal: Mult Scler Relat Disord Date: 2021-04-09 Impact factor: 4.808

Review 4. The role of the ubiquitin-editing enzyme A20 in diseases of the central nervous system and other pathological processes.

Authors: Asghar Abbasi; Kirsi Forsberg; Felix Bischof
Journal: Front Mol Neurosci Date: 2015-06-15 Impact factor: 5.639

Multiple sclerosis in the context of TNF blockade and inflammatory bowel disease.

1. Interaction of *HLA-DRB1***1501* and TNF-Alpha in a Population-based Case-control Study of Multiple Sclerosis.

Review 2. Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping.

3. Use of anti-TNF-α therapy in Crohn's disease is associated with increased incidence of multiple sclerosis.

Review 4. The role of the ubiquitin-editing enzyme A20 in diseases of the central nervous system and other pathological processes.

Review 5. CNS Demyelination with TNF-α Blockers.

6. Pathogenic T cell cytokines in multiple sclerosis.

7. PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders.

Multiple sclerosis in the context of TNF blockade and inflammatory bowel disease.

1. Interaction of HLA-DRB1*1501 and TNF-Alpha in a Population-based Case-control Study of Multiple Sclerosis.

Review 2. Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping.

3. Use of anti-TNF-α therapy in Crohn's disease is associated with increased incidence of multiple sclerosis.

Review 4. The role of the ubiquitin-editing enzyme A20 in diseases of the central nervous system and other pathological processes.

Review 5. CNS Demyelination with TNF-α Blockers.

6. Pathogenic T cell cytokines in multiple sclerosis.

7. PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders.

1. Interaction of *HLA-DRB1***1501* and TNF-Alpha in a Population-based Case-control Study of Multiple Sclerosis.